CONMED Corporation announced that Chief Financial Officer Todd Garner will step down effective March 15, 2026, and will serve in an advisory capacity through November 2, 2026. The announcement was made on January 8, 2026, and the transition is part of the company’s broader effort to reinforce its leadership team as it pursues margin repair and growth initiatives in its orthopedic and general surgery businesses.
Garner, who has led the company’s finance function for eight years, has been credited with strengthening CONMED’s financial foundation and supporting strategic initiatives that position the company for scalable, long‑term growth. CEO Pat Beyer said, “Todd has been instrumental in strengthening our financial foundation and supporting strategic initiatives that position CONMED for scalable, long‑term growth. We are grateful for his commitment to ensuring a seamless transition.”
CONMED has engaged a leading executive‑search firm to identify a permanent replacement. The search will focus on candidates with experience in the medical‑technology sector and a track record of driving profitability and capital discipline, reflecting the company’s emphasis on margin repair.
The CFO transition comes as CONMED continues to execute a portfolio optimization strategy that includes the exit from its gastroenterology product lines and the termination of its distribution agreement for the VIABIL biliary stent. These moves are intended to sharpen focus on core orthopedic and general surgery markets, where the company has reported solid revenue growth and improving margins.
In its most recent quarterly results, CONMED reported third‑quarter revenue of $337.9 million, up 6.7% year‑over‑year, and adjusted diluted earnings per share of $1.08, beating analyst estimates of $1.05 by $0.03. Gross margin stood at 56.5%, operating margin at 11.4%, and net margin at 4.8%, reflecting disciplined cost management and a favorable product mix. CONMED reaffirmed its full‑year 2025 revenue and adjusted EPS guidance issued on November 5, 2025, signaling confidence in continued performance amid the leadership transition.
The company’s focus on margin repair and growth initiatives is underscored by its recent strategic exits and the ongoing search for a CFO who can sustain financial discipline while supporting the company’s expansion plans. Management’s emphasis on a seamless transition and the reaffirmation of guidance suggest that the leadership change is viewed as a routine succession rather than a disruption to the company’s trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.